1-s2.0-088539249500087F-main.pdf
| Assessment Criterion | AI Analysis | AI Judgment | Issues |
|---|---|---|---|
|
Was a consecutive or random sample of patients enrolled?
ds_d1_rb1
|
The study explicitly states that it is a 'prospective, consecutive series of patients' (P2.L17), which meets the NOS criterion for a consecutive sample. This reduces selection bias by including all eligible patients over a defined period. The text also describes enrollment over a specific time frame ('Patients with exclusively neuropathic pain were enrolled over a 4-year period (7/89-9/92)', P2.L32-L34), further supporting systematic, consecutive recruitment. No evidence of convenience sampling or case-control design is present.
|
star awarded | |
|
Was a case-control design avoided?
ds_d1_rb2
|
The study is a prospective cohort study, not a case-control design. However, the NOS item 'Was a case-control design avoided?' is not a standard NOS item for cohort studies. The NOS for cohort studies does not include a criterion about avoiding case-control design; instead, it assesses selection, comparability, and outcome. The document explicitly states 'This report presents a prospective, consecutive series of patients' (P2.L16-L18), indicating a cohort design. Since the criterion is not applicable to cohort studies, no star is awarded. The guidance provided ('Case-control designs can overestimate diagnostic accuracy') is irrelevant to this study's design.
|
no star awarded | |
|
Did the study avoid inappropriate exclusions?
ds_d1_rb3
|
Raw response parsing failed. Original content: {
"judgment": "star awarded",
"scoring_rationale": "The study explicitly describes inclusion and exclusion criteria, and the exclusions are appropriate for the research question. Inclusion criteri...
|
no | |
|
Are there concerns that the included patients and setting do not match the review question?
ds_d1_ac1
|
The study does not provide sufficient explicit information about the patient population and setting to determine if they match a specific review question. The document describes a cohort of patients with exclusively neuropathic pain who underwent intraspinal opioid infusions, but it does not define a review question or specify the intended use of the index test (intraspinal opioid infusion) in a broader context. The patient characteristics are described (e.g., diagnoses, inclusion/exclusion criteria), but without a clear review question, it is impossible to assess matching. Therefore, no star is awarded.
|
no star awarded | |
|
Were the index test results interpreted without knowledge of the results of the reference standard?
ds_d2_rb1
|
The document explicitly states that the most-recent patient evaluation of the 'success' patients was conducted by a disinterested third party who had never previously contacted any of the patients and will not be involved in their future care. This indicates that the outcome assessment was blinded to the reference standard (preimplant condition) and performed by an independent evaluator, meeting the NOS criterion for blinding of outcome assessment.
|
star awarded | |
|
If a threshold was used, was it pre-specified?
ds_d2_rb2
|
The document does not explicitly state that a threshold for defining success or failure was pre-specified before data collection or analysis. Although a threshold of 'at least 25% reduction in NRS rating' is mentioned as the criterion for success, there is no statement indicating that this threshold was established a priori (i.e., before the study began). The text describes the threshold as part of the evaluation criteria but does not confirm pre-specification. Without explicit evidence of pre-specification, a star cannot be awarded.
|
no star awarded | |
|
Are there concerns that the index test, its conduct, or interpretation differ from the review question?
ds_d2_ac1
|
This criterion is not directly applicable to the Newcastle-Ottawa Scale (NOS) for cohort studies. The NOS assesses selection, comparability, and outcome domains, not the index test or its conduct relative to a review question. The document describes a prospective cohort study evaluating long-term intraspinal opioid infusions for neuropathic pain. The index test (intraspinal opioid infusion) is performed as it would be in practice, with a trial infusion followed by pump implantation for those with >50% pain relief. However, the NOS does not have a specific item for this criterion. Therefore, no star is awarded.
|
no star awarded | |
|
Is the reference standard likely to correctly classify the target condition?
ds_d3_rb1
|
The reference standard for classifying the target condition (neuropathic pain) is not explicitly described. The document mentions that patients had 'exclusively neuropathic pain' and were assessed by a multidisciplinary group, but does not specify a single, best-available reference standard (e.g., specific diagnostic criteria, validated pain assessment tool, or independent expert panel) used to confirm the presence of neuropathic pain. Without clear documentation of the reference standard, it is not possible to determine if it is likely to correctly classify the target condition.
|
no star awarded | |
|
Were the reference standard results interpreted without knowledge of the results of the index test?
ds_d3_rb2
|
The criterion requires that the reference standard results be interpreted without knowledge of the index test results. The document describes that a disinterested third party (D.S.C.) conducted the most-recent patient evaluation for 'success' patients, but it does not explicitly state that this evaluator was blinded to the index test results (i.e., the results of the intrathecal opioid trial or the preimplant pain ratings). The text only states that the third party had never contacted the patients and would not be involved in future care, but it does not mention blinding to the index test. Without explicit evidence of blinding, the conservative judgment is that the criterion is not met.
|
no star awarded | |
|
Are there concerns that the target condition as defined by the reference standard does not match the question?
ds_d3_ac1
|
The NOS item asks whether the reference standard defines the same target condition as in the review question. In this study, the reference standard for defining the target condition (neuropathic pain) is not explicitly described. The document states that patients had 'exclusively neuropathic pain' (P2.L32) and were evaluated by a multidisciplinary group, but no specific diagnostic criteria, validated scale, or reference standard for confirming neuropathic pain is mentioned. Without explicit documentation of how neuropathic pain was diagnosed or confirmed, it is impossible to determine if the reference standard matches the review question. Therefore, no star is awarded.
|
no star awarded | |
|
Was there an appropriate interval between index test and reference standard?
ds_d4_rb1
|
The document does not describe an index test and reference standard with a specified interval. Instead, it reports a case series of patients receiving intraspinal opioid infusions for neuropathic pain, with follow-up assessments at variable times (e.g., 'mean follow-up 2.4 ± 0.3 yrs', 'last follow-up'). There is no mention of a separate index test or reference standard, nor any interval between them. Therefore, the criterion 'appropriate interval between index test and reference standard' is not applicable, and no star can be awarded.
|
no star awarded | |
|
Did all patients receive the same reference standard?
ds_d4_rb2
|
The document does not describe any reference standard (e.g., a gold standard diagnostic test) applied to patients. The study is a case series evaluating pain relief from intraspinal opioid infusions, not a diagnostic accuracy study. Therefore, the criterion 'Did all patients receive the same reference standard?' is not applicable, and no star can be awarded.
|
no star awarded | |
|
Were all patients included in the analysis?
ds_d4_rb3
|
The study explicitly states that no patients were lost to follow-up, and the reasons for withdrawal (failure of trial infusion, failure of long-term pain relief) are clearly described. The follow-up procedures are detailed, including regular monthly visits for the first 6 months and ongoing evaluations for pump refills. The text provides direct evidence that all enrolled patients were accounted for in the analysis, with no unexplained attrition.
|
star awarded |